Singapore markets close in 53 minutes

The Trendlines Group Ltd. (42T.SI)

SES - SES Delayed price. Currency in SGD
Add to watchlist
0.06700.0000 (0.00%)
As of 03:24PM SGT. Market open.
Full screen
Previous close0.0670
Open0.0660
Bid0.0680 x 0
Ask0.0680 x 0
Day's range0.0660 - 0.0680
52-week range0.0596 - 0.1050
Volume2,225,300
Avg. volume513,622
Market cap64.72M
Beta (5Y monthly)0.77
PE ratio (TTM)N/A
EPS (TTM)-0.0500
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Ceretrieve Announces Groundbreaking Success in FIH Ischemic Stroke Cases

    Ceretrieve announced today the successful results of the company's multicenter, single-arm study, showcasing the capabilities of its state-of-the-art aspiration catheter. The study, conducted across two centers, included 20 patients who suffered from acute ischemic stroke (AIS) due to intracranial large vessel occlusion (LVO) and were eligible for thrombectomy within 24 hours of symptom onset. The study was aimed for assessing the safety and initial performance of the Ceretrieve Device.

  • PR Newswire

    Limaca Medical Completes 24 EUS Pancreatic and Liver Biopsy Cases

    Limaca Medical ("Limaca") announced today the successful completion of twenty-four Precision-GI™ endoscopic ultrasound guided motorized fine needle biopsy (EUS-mFNB) cases. Precision-GI's motorized rotational cutting needle demonstrated significant tissue acquisition. Cases completed by Dr. Carlos Robles-Medranda and colleagues in the ongoing study demonstrate that Precision-GI is quickly and efficiently obtaining contiguous intact core tissue samples for definitive diagnosis of target tissues.

  • PR Newswire

    ZygoFix Receives FDA Clearance for its zLOCK Lumbar Facet Fixation System

    ZygoFix Ltd. a portfolio company of The Trendlines Group Ltd. ("Trendlines") announced that it received regulatory clearance from the United States Food and Drug Administration (FDA clearance) for its zLOCK Lumbar Facet Fixation System. This achievement was supported by compelling clinical evidence from the company's ongoing European clinical study, marking a significant advancement in spinal fusion technology.